Edwards Lifesciences (NYSE:EW) Releases Q1 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.580-0.640 for the period, compared to the consensus earnings per share estimate of 0.590. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Edwards Lifesciences also updated its FY 2025 guidance to 2.400-2.500 EPS.

Analysts Set New Price Targets

Several research firms recently issued reports on EW. Piper Sandler dropped their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Trading Down 0.2 %

Shares of EW stock traded down $0.15 during trading hours on Tuesday, reaching $70.95. 3,405,627 shares of the stock traded hands, compared to its average volume of 4,396,275. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a fifty day moving average price of $72.46 and a 200 day moving average price of $69.26. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $41.85 billion, a PE ratio of 10.24, a PEG ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, equities research analysts forecast that Edwards Lifesciences will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.